Fig. 2

Flow diagram of the process to identify effective medications supported by high- or moderate-quality evidence. ^aStatistically significant at the p < 0.05 level. ^bEstimates were for subgroup estimates that did not meet our criteria for quality assessment. ^cSubgroup or sensitivity analysis as defined by authors. ^dPre-specified in the methods section of the review article. ^eUnique at the level of pharmacological subgroup in the World Health Organization’s Anatomical Therapeutic Chemical classification system. ^fUnique at the three-character coding level using the World Health Organization’s 10th revision of the International Statistical Classification of Diseases and Related Health Problems